Abstracts Highlighting Data from Enzon Pharmaceuticals, Inc.'s mRNA Antagonist Programs Accepted for Presentation at 2010 European Organization for Research and Treatment of Cancer-National Cancer Institute-American Association for Cancer Research Meeting

BRIDGEWATER, N.J.--(BUSINESS WIRE)--Enzon Pharmaceuticals, Inc. (Nasdaq: ENZN) today announced that data from preclinical studies of three investigational messenger RNA (mRNA) antagonists based on the locked nucleic acid (LNA) technology platform have been accepted for poster presentation at the EORTC-NCI-AACR International Symposium on Molecular Targets and Cancer Therapeutics, which is being held November 16-19 in Berlin, Germany.